About the Authors
- Frédéric Coutant
-
Current address: Faculté de médecine Paris Descartes, Paris, France
Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
- Raul Yusef Sanchez David
-
Current address: Unité de Génomique Virale et Vaccination, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
- Tristan Félix
-
Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
- Aude Boulay
-
Current address: Service d’Epidémiologie, Institut Pasteur de Bangui, BP 923 Bangui, République Centrafricaine
Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
- Laxmee Caleechurn
-
Current address: Laboratoires Clarins S.A., BP147, 95304 Cergy Pontoise Cedex, France
Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
- Philippe Souque
-
Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
- Catherine Thouvenot
-
Affiliation Centre de Production et d’Infection des Anophèles (CEPIA), Department of Parasitology and Mycology, Institut Pasteur, Paris, France
- Catherine Bourgouin
-
Affiliation Centre de Production et d’Infection des Anophèles (CEPIA), Department of Parasitology and Mycology, Institut Pasteur, Paris, France
- Anne-Sophie Beignon
-
Contributed equally to this work with: Anne-Sophie Beignon, Pierre Charneau
* E-mail: asb@pasteur.fr (ASB); pierre.charneau@pasteur.fr (PC)
Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
- Pierre Charneau
-
Contributed equally to this work with: Anne-Sophie Beignon, Pierre Charneau
* E-mail: asb@pasteur.fr (ASB); pierre.charneau@pasteur.fr (PC)
Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
Competing Interests
We have read the journal’s policy and have the following conflicts. PC is the founder of theravectys, a company whose goal is to develop a therapeutic AIDS vaccine using lentiviral vectors. FC and PC are inventors of a patent titled “Lentiviral vector based immunological compounds against malaria” (international patent application W02011138251 filed on April 24, 2011) and which is owned by the Institut Pasteur. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: FC CB ASB PC. Performed the experiments: FC RYSD TF AB LC PS CT ASB. Analyzed the data: FC CB ASB PC. Contributed reagents/materials/analysis tools: CB. Wrote the paper: FC CB ASB PC.